Schedule 13G ownership disclosure
Eikon Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 282564103
Event date: 2026-02-04
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Abu Dhabi Investment Authority
Shares: 2,816,714.00 · Class: 5.2%
- Platinum Falcon B 2018 RSC Limited
Shares: 1,147,138.00 · Class: 2.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-26-003632
- Form type
- SCHEDULE 13G
- Filer
- Abu Dhabi Investment Authority
- CIK
- CIK 1362558
- Filed
- Feb 18, 2026
- Reporting period
- Feb 04, 2026
- Description
- Schedule 13G beneficial ownership